Skip to main content
Top
Published in: Endocrine 3/2020

01-09-2020 | Original Article

Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells

Authors: Walaa Alshafie, Yingzhou Edward Pan, Hans-Jürgen Kreienkamp, Thomas Stroh

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Background

Somatostatin (SOM) receptor subtype 2 (SSTR2) is the major receptor subtype mediating SOM effects throughout the neuraxis. We previously demonstrated that the non-selective agonist [D-Trp8]-SOM induces intracellular sequestration of SSTR2, whereas this receptor is maintained at the cell surface after treatment with the SSTR2-selective agonist L-779,976 in cells co-expressing SSTR2 and SSTR5.

Methods and results

In this study, we knocked-out SSTR5 in AtT20 cells endogenously expressing both SSTR2 and SSTR5 and used immuno-labeling and confocal microscopy to investigate the effect of SSTR5 on regulation of SSTR2 trafficking. Our results indicate that unlike [D-Trp8]-SOM-induced intracellular sequestration, L-779,976 stimulation results in the maintenance of SSTR2 at the cell surface regardless of whether SSTR5 is present or not. We then examined the trafficking pathways of SSTR2 upon stimulation by either agonist. We found that both [D-Trp8]-SOM and L-779,976 induce SSTR2 internalization via transferrin-positive vesicles. However, SSTR2 internalized upon L-779,976 treatment undergoes rapid recycling to the plasma membrane, whereas receptors internalized by [D-Trp8]-SOM recycle slowly after washout of the agonist. Furthermore, [D-Trp8]-SOM stimulation induces degradation of a fraction of internalized SSTR2 whereas L-779,976-dependent, rapid SSTR2 recycling appears to protect internalized SSTR2 from degradation. In addition, Octreotide which has preferential SSTR2 affinity, induced differential effects on both SSTR2 trafficking and degradation.

Conclusion

Our results indicate that the biased agonistic property of L-779,976 protects against SSTR2 surface depletion by rapidly initiating SSTR2 recycling while SSTR5 does not regulate L-779-976-dependent SSTR2 trafficking.
Appendix
Available only for authorised users
Literature
1.
go back to reference G. Olias et al. Regulation and function of somatostatin receptors. J. Neurochem 89(5), 1057–1091 (2004)PubMed G. Olias et al. Regulation and function of somatostatin receptors. J. Neurochem 89(5), 1057–1091 (2004)PubMed
2.
go back to reference P. Brazeau et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(4068), 77–79 (1973)PubMed P. Brazeau et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(4068), 77–79 (1973)PubMed
3.
go back to reference Z. Csaba, P. Dournaud, Cellular biology of somatostatin receptors. Neuropeptides 35(1), 1–23 (2001)PubMed Z. Csaba, P. Dournaud, Cellular biology of somatostatin receptors. Neuropeptides 35(1), 1–23 (2001)PubMed
4.
go back to reference L.J. Hofland, S.W. Lamberts, The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24(1), 28–47 (2003)PubMed L.J. Hofland, S.W. Lamberts, The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24(1), 28–47 (2003)PubMed
5.
go back to reference S.W. Lamberts, Conclusions: the future role of somatostatin analogs. J. Endocrinol. Investig. 26(8 Suppl), 134–135 (2003) S.W. Lamberts, Conclusions: the future role of somatostatin analogs. J. Endocrinol. Investig. 26(8 Suppl), 134–135 (2003)
6.
go back to reference G. Tulipano et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 279(20), 21374–21382 (2004)PubMed G. Tulipano et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 279(20), 21374–21382 (2004)PubMed
7.
go back to reference S. Brasselet et al. Beta-arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cells. FEBS Lett. 516(1–3), 124–128 (2002)PubMed S. Brasselet et al. Beta-arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cells. FEBS Lett. 516(1–3), 124–128 (2002)PubMed
8.
go back to reference S.J. Mundell, J.L. Benovic, Selective regulation of endogenous G protein-coupled receptors by arrestins in HEK293 cells. J. Biol. Chem. 275(17), 12900–12908 (2000)PubMed S.J. Mundell, J.L. Benovic, Selective regulation of endogenous G protein-coupled receptors by arrestins in HEK293 cells. J. Biol. Chem. 275(17), 12900–12908 (2000)PubMed
9.
go back to reference Z. Csaba et al. Activated somatostatin type 2 receptors traffic in vivo in central neurons from dendrites to the trans Golgi before recycling. Traffic 8(7), 820–834 (2007)PubMed Z. Csaba et al. Activated somatostatin type 2 receptors traffic in vivo in central neurons from dendrites to the trans Golgi before recycling. Traffic 8(7), 820–834 (2007)PubMed
10.
go back to reference N. Sharif et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148(5), 2095–2105 (2007)PubMed N. Sharif et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148(5), 2095–2105 (2007)PubMed
11.
go back to reference S. Lesche et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94(2), 654–661 (2009)PubMed S. Lesche et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94(2), 654–661 (2009)PubMed
13.
go back to reference O.F. Kuzu et al. Effect of lysosomotropic molecules on cellular homeostasis. Pharmacol. Res 117, 177–184 (2017)PubMed O.F. Kuzu et al. Effect of lysosomotropic molecules on cellular homeostasis. Pharmacol. Res 117, 177–184 (2017)PubMed
14.
go back to reference D.H. Lee, A.L. Goldberg, Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8(10), 397–403 (1998)PubMed D.H. Lee, A.L. Goldberg, Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8(10), 397–403 (1998)PubMed
15.
go back to reference H.H. Mollenhauer, D.J. Morré, L.D. Rowe, Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys. Acta 1031(2), 225–246 (1990)PubMed H.H. Mollenhauer, D.J. Morré, L.D. Rowe, Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys. Acta 1031(2), 225–246 (1990)PubMed
16.
go back to reference D. Nouel et al. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138(1), 296–306 (1997)PubMed D. Nouel et al. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138(1), 296–306 (1997)PubMed
17.
go back to reference T. Stroh et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology 141(1), 354–365 (2000)PubMed T. Stroh et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology 141(1), 354–365 (2000)PubMed
18.
go back to reference M. Pfeiffer et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276(17), 14027–14036 (2001)PubMed M. Pfeiffer et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276(17), 14027–14036 (2001)PubMed
19.
go back to reference K.W. Dunn, M.M. Kamocka, J.H. McDonald, A practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 300(4), C723–C742 (2011)PubMedPubMedCentral K.W. Dunn, M.M. Kamocka, J.H. McDonald, A practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 300(4), C723–C742 (2011)PubMedPubMedCentral
20.
go back to reference J. Cordoba-Chacon et al. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol. Life Sci. 67(7), 1147–1163 (2010)PubMed J. Cordoba-Chacon et al. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol. Life Sci. 67(7), 1147–1163 (2010)PubMed
21.
go back to reference K.M. Mayle, A.M. Le, D.T. Kamei, The intracellular trafficking pathway of transferrin. Biochim Biophys. Acta 1820(3), 264–281 (2012)PubMed K.M. Mayle, A.M. Le, D.T. Kamei, The intracellular trafficking pathway of transferrin. Biochim Biophys. Acta 1820(3), 264–281 (2012)PubMed
22.
go back to reference W. Alshafie et al. Regulated resurfacing of a somatostatin receptor storage compartment fine-tunes pituitary secretion. J. Cell Biol 219(1), e201904054 (2020)PubMed W. Alshafie et al. Regulated resurfacing of a somatostatin receptor storage compartment fine-tunes pituitary secretion. J. Cell Biol 219(1), e201904054 (2020)PubMed
23.
go back to reference Z. Csaba et al. In vivo internalization of the somatostatin sst2A receptor in rat brain: evidence for translocation of cell-surface receptors into the endosomal recycling pathway. Mol. Cell Neurosci. 17(4), 646–661 (2001)PubMed Z. Csaba et al. In vivo internalization of the somatostatin sst2A receptor in rat brain: evidence for translocation of cell-surface receptors into the endosomal recycling pathway. Mol. Cell Neurosci. 17(4), 646–661 (2001)PubMed
24.
go back to reference Z. Csaba et al. Targeting sst2A receptor-expressing cells in the rat hypothalamus through in vivo agonist stimulation: neuroanatomical evidence for a major role of this subtype in mediating somatostatin functions. Endocrinology 144(4), 1564–1573 (2003)PubMed Z. Csaba et al. Targeting sst2A receptor-expressing cells in the rat hypothalamus through in vivo agonist stimulation: neuroanatomical evidence for a major role of this subtype in mediating somatostatin functions. Endocrinology 144(4), 1564–1573 (2003)PubMed
25.
go back to reference Z. Csaba et al. Neurochemical characterization of receptor-expressing cell populations by in vivo agonist-induced internalization: insights from the somatostatin sst2A receptor. J. Comp. Neurol. 454(2), 192–199 (2002)PubMed Z. Csaba et al. Neurochemical characterization of receptor-expressing cell populations by in vivo agonist-induced internalization: insights from the somatostatin sst2A receptor. J. Comp. Neurol. 454(2), 192–199 (2002)PubMed
26.
go back to reference J.P. Hannon et al. Somatostatin sst2 receptor knock-out mice: localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography. Neuropharmacology 42(3), 396–413 (2002)PubMed J.P. Hannon et al. Somatostatin sst2 receptor knock-out mice: localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography. Neuropharmacology 42(3), 396–413 (2002)PubMed
27.
go back to reference M.Z. Strowski et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 75(6), 339–346 (2002)PubMed M.Z. Strowski et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 75(6), 339–346 (2002)PubMed
28.
go back to reference M. Tallent et al. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 71(4), 1073–1081 (1996)PubMed M. Tallent et al. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 71(4), 1073–1081 (1996)PubMed
29.
go back to reference D. Cervia et al. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br. J. Pharmacol. 139(1), 109–121 (2003)PubMedPubMedCentral D. Cervia et al. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br. J. Pharmacol. 139(1), 109–121 (2003)PubMedPubMedCentral
30.
go back to reference A. Ben-Shlomo et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J. Biol. Chem. 280(25), 24011–24021 (2005)PubMed A. Ben-Shlomo et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J. Biol. Chem. 280(25), 24011–24021 (2005)PubMed
31.
go back to reference A. Ben-Shlomo et al. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol. Endocrinol. 21(10), 2565–2578 (2007)PubMed A. Ben-Shlomo et al. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol. Endocrinol. 21(10), 2565–2578 (2007)PubMed
32.
go back to reference M. Korner et al. A critical evaluation of sst3 and sst5 immunohistochemistry in human pituitary adenomas. Neuroendocrinology 106(2), 116–127 (2018)PubMed M. Korner et al. A critical evaluation of sst3 and sst5 immunohistochemistry in human pituitary adenomas. Neuroendocrinology 106(2), 116–127 (2018)PubMed
33.
go back to reference Q. Liu et al. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol. Pharmacol. 68(1), 90–101 (2005)PubMed Q. Liu et al. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol. Pharmacol. 68(1), 90–101 (2005)PubMed
34.
go back to reference M. Grant et al. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22(10), 2278–2292 (2008)PubMedPubMedCentral M. Grant et al. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22(10), 2278–2292 (2008)PubMedPubMedCentral
35.
go back to reference F. Poll et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol. Endocrinol. 24(2), 436–446 (2010)PubMedPubMedCentral F. Poll et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol. Endocrinol. 24(2), 436–446 (2010)PubMedPubMedCentral
36.
go back to reference A. Mohamed et al. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr. Relat. Cancer 21(5), 691–704 (2014)PubMed A. Mohamed et al. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr. Relat. Cancer 21(5), 691–704 (2014)PubMed
37.
go back to reference B. Waser et al. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients. Am. J. Pathol. 180(5), 1942–1949 (2012)PubMedPubMedCentral B. Waser et al. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients. Am. J. Pathol. 180(5), 1942–1949 (2012)PubMedPubMedCentral
38.
go back to reference I.R. Wallace et al. TSH-secreting pituitary adenoma: benefits of pre-operative octreotide. Endocrinol. Diabetes Metab. Case Rep. 2015, 150007 (2015)PubMedPubMedCentral I.R. Wallace et al. TSH-secreting pituitary adenoma: benefits of pre-operative octreotide. Endocrinol. Diabetes Metab. Case Rep. 2015, 150007 (2015)PubMedPubMedCentral
39.
go back to reference J.C. Reubi, A. Schonbrunn, Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol. Sci. 34(12), 676–688 (2013)PubMed J.C. Reubi, A. Schonbrunn, Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol. Sci. 34(12), 676–688 (2013)PubMed
40.
go back to reference D. Cuevas-Ramos, M. Fleseriu, Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J. Mol. Endocrinol. 52(3), R223–R240 (2014)PubMed D. Cuevas-Ramos, M. Fleseriu, Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J. Mol. Endocrinol. 52(3), R223–R240 (2014)PubMed
41.
go back to reference S.W. Lamberts, A.J. van der Lely, L.J. Hofland, New somatostatin analogs: will they fulfil old promises? Eur. J. Endocrinol. 146(5), 701–705 (2002)PubMed S.W. Lamberts, A.J. van der Lely, L.J. Hofland, New somatostatin analogs: will they fulfil old promises? Eur. J. Endocrinol. 146(5), 701–705 (2002)PubMed
42.
go back to reference Z.R. Qian et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 45(10), 1386–1393 (2016)PubMedPubMedCentral Z.R. Qian et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 45(10), 1386–1393 (2016)PubMedPubMedCentral
43.
go back to reference B. Yu et al. Clinical importance of somatostatin receptor 2 (SSTR2) and somatostatin receptor 5 (SSTR5) expression in thyrotropin-producing pituitary adenoma (TSHoma). Med Sci. Monit. 23, 1947–1955 (2017)PubMedPubMedCentral B. Yu et al. Clinical importance of somatostatin receptor 2 (SSTR2) and somatostatin receptor 5 (SSTR5) expression in thyrotropin-producing pituitary adenoma (TSHoma). Med Sci. Monit. 23, 1947–1955 (2017)PubMedPubMedCentral
44.
go back to reference W. Liu et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues. Int J. Endocrinol. 2017, 9606985 (2017)PubMedPubMedCentral W. Liu et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues. Int J. Endocrinol. 2017, 9606985 (2017)PubMedPubMedCentral
45.
go back to reference Z. Csaba et al. Somatostatin receptor type 2 undergoes plastic changes in the human epileptic dentate gyrus. J. Neuropathol. Exp. Neurol. 64(11), 956–969 (2005)PubMed Z. Csaba et al. Somatostatin receptor type 2 undergoes plastic changes in the human epileptic dentate gyrus. J. Neuropathol. Exp. Neurol. 64(11), 956–969 (2005)PubMed
46.
go back to reference D. Cervia, G. Casini, P. Bagnoli, Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol. Cell. Endocrinol. 286(1), 112–122 (2008)PubMed D. Cervia, G. Casini, P. Bagnoli, Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol. Cell. Endocrinol. 286(1), 112–122 (2008)PubMed
Metadata
Title
Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells
Authors
Walaa Alshafie
Yingzhou Edward Pan
Hans-Jürgen Kreienkamp
Thomas Stroh
Publication date
01-09-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02329-x

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.